Trials / Active Not Recruiting
Active Not RecruitingNCT05840016
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 532 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112, Carboplatin, Paxlitaxel | IV infusion,Specified dose on specified days |
| DRUG | Tislelizumab, Carboplatin, Paxlitaxel | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2023-08-17
- Primary completion
- 2025-02-28
- Completion
- 2026-12-31
- First posted
- 2023-05-03
- Last updated
- 2025-05-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05840016. Inclusion in this directory is not an endorsement.